Andrea Marie Reyes
St. Lukes Medical Center, Philippines
Title: Efficacy of nicorandil in the prevention of contrast-induced nephropathy among patients with chronic kidney disease undergoing coronary angiography: A meta-analysis of randomized controlled trials
Biography
Biography: Andrea Marie Reyes
Abstract
Contrast-Induced Nephropathy (CIN) is a reversible form of acute kidney injury that occurs soon after the administration of
contrast media. Currently accepted methods for prevention of CIN include intravenous (IV) hydration, administration of
oral n-acetylcysteine and use of atorvastatin. Nicorandil, a novel anti-angina drug has been studied to have a beneficial effect
as well in preventing CIN. This paper aims to determine the efficacy of Nicorandil in preventing the incidence of contrast-induced
nephropathy in patients who will undergo coronary angiography. Search for randomized controlled trials was done,
evaluating the efficacy of Nicorandil in preventing contrast-induced nephropathy in patients undergoing coronary angiography.
Articles were critically appraised for inclusion. Pooled analysis revealed a Chi2 value of 4.32, dF =3 (P=0.21), I2 of 31%.
The computed relative risk for incidence of CIN following Nicorandil administrations was 38% (CI: 0.19, 0.71). Administration of
Nicorandil showed absolute risk reduction in the incidence of CIN by 8% as compared to IV hydration seen in the Forest plot with
a number needed to treat of 12. It showed a trend favoring Nicorandil for the prevention of contrast-induced nephropathy. The
studies also showed that Nicorandil together with IV hydration significantly caused the reduction in cystatin C levels and change
from baseline eGFR as compared with standard intravenous hydration.